Thoughts on Medexus Heading Into Earnings Next Week

Last week, we received some news that Medexus (MEDXF) received a complete response letter from the FDA which will delay ultimate approval for Treosulfan.

Are you a member but not signed in? Click here to sign into your account.

Not a Member yet? Click here to learn about our service.

Our Members enjoy exclusive access to detailed analysis on under-the-radar spin-offs before they are profiled on Seeking Alpha, Value Investor Club, or SumZero.

Join Now